{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:33:45Z","timestamp":1785170025719,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00417-020-05028-5","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T14:19:56Z","timestamp":1609942796000},"page":"1821-1830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Difference in treatment burden of neovascular age-related macular degeneration among different types of neovascularization"],"prefix":"10.1007","volume":"259","author":[{"given":"Ji Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-6353","authenticated-orcid":false,"given":"Jae Hui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"5028_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0002-9394(82)90410-X","volume":"93","author":"SB Bressler","year":"1982","unstructured":"Bressler SB, Bressler NM, Fine SL, Hillis A, Murphy RP, Olk RJ, Patz A (1982) Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 93:157\u2013163","journal-title":"Am J Ophthalmol"},{"key":"5028_CR2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/archopht.1986.01050170092029","volume":"104","author":"DR Guyer","year":"1986","unstructured":"Guyer DR, Fine SL, Maguire MG, Hawkins BS, Owens SL, Murphy RP (1986) Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol 104:702\u2013705","journal-title":"Arch Ophthalmol"},{"key":"5028_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamaophthalmol.2013.7647","volume":"132","author":"FA Sloan","year":"2014","unstructured":"Sloan FA, Hanrahan BW (2014) The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration. JAMA Ophthalmol 132:456\u2013463","journal-title":"JAMA Ophthalmol"},{"key":"5028_CR4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"JM Colijn","year":"2017","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, Cougnard-Gregoire A, Merle BMJ, Korb C, Erke MG, Bron A, Anastasopoulos E, Meester-Smoor MA, Segato T, Piermarocchi S, de Jong P, Vingerling JR, Topouzis F, Creuzot-Garcher C, Bertelsen G, Pfeiffer N, Fletcher AE, Foster PJ, Silva R, Korobelnik JF, Delcourt C, Klaver CCW (2017) Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology 124:1753\u20131763","journal-title":"Ophthalmology"},{"key":"5028_CR5","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1167\/iovs.05-1467","volume":"47","author":"JF Korobelnik","year":"2006","unstructured":"Korobelnik JF, Moore N, Blin P, Dharmani C, Berdeaux G (2006) Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a markov model. Invest Ophthalmol Vis Sci 47:4270\u20134276","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5028_CR6","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116","journal-title":"Lancet Glob Health"},{"key":"5028_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/IAE.0b013e3181669504","volume":"28","author":"KB Freund","year":"2008","unstructured":"Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, Matsumoto Y, Sorenson JA, Yannuzzi L (2008) Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 28:201\u2013211","journal-title":"Retina"},{"key":"5028_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","volume":"21","author":"LA Yannuzzi","year":"2001","unstructured":"Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416\u2013434","journal-title":"Retina"},{"key":"5028_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/bjo.2007.115501","volume":"91","author":"SY Cohen","year":"2007","unstructured":"Cohen SY, Creuzot-Garcher C, Darmon J, Desmettre T, Korobelnik JF, Levrat F, Quentel G, Palies S, Sanchez A, de Gendre AS, Schluep H, Weber M, Delcourt C (2007) Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol 91:1173\u20131176","journal-title":"Br J Ophthalmol"},{"key":"5028_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00417-018-04228-4","volume":"257","author":"JH Kim","year":"2019","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2019) Age-related differences in the prevalence of subtypes of neovascular age-related macular degeneration in the first diagnosed eye. Graefes Arch Clin Exp Ophthalmol 257:891\u2013898","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5028_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15\u201322","journal-title":"Am J Ophthalmol"},{"key":"5028_CR12","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1097\/IAE.0b013e3181bfbd46","volume":"29","author":"M Engelbert","year":"2009","unstructured":"Engelbert M, Zweifel SA, Freund KB (2009) \u201cTreat and extend\u201d dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation. Retina 29:1424\u20131431","journal-title":"Retina"},{"key":"5028_CR13","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1097\/IAE.0000000000001876","volume":"38","author":"JH Kim","year":"2018","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW, Cho SY (2018) Difference in treatment outcomes according to optical coherence tomography-based stages in type 3 neovascularization (retinal angiomatous proliferation). Retina 38:2356\u20132362","journal-title":"Retina"},{"key":"5028_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1\u20138","journal-title":"Retina"},{"key":"5028_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000774","volume":"36","author":"C Balaratnasingam","year":"2016","unstructured":"Balaratnasingam C, Lee WK, Koizumi H, Dansingani K, Inoue M, Freund KB (2016) Polypoidal choroidal vasculopathy: a distinct disease or manifestation of many? Retina 36:1\u20138","journal-title":"Retina"},{"key":"5028_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.oret.2018.08.008","volume":"3","author":"M Li","year":"2019","unstructured":"Li M, Dolz-Marco R, Messinger JD, Sloan KR, Ferrara D, Curcio CA, Freund KB (2019) Clinicopathologic correlation of aneurysmal type 1 neovascularization in age-related macular degeneration. Ophthalmol Retina 3:99\u2013111","journal-title":"Ophthalmol Retina"},{"key":"5028_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, Gomi F, Koh AH, Lee WK, Wong TY (2018) Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology 125:708\u2013724","journal-title":"Ophthalmology"},{"issue":"939\u2013946","key":"5028_CR18","volume":"149","author":"IA Barbazetto","year":"2010","unstructured":"Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB (2010) Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 149(939\u2013946):e931","journal-title":"Am J Ophthalmol"},{"key":"5028_CR19","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1111\/aos.12748","volume":"94","author":"YS Chang","year":"2016","unstructured":"Chang YS, Kim JH, Yoo SJ, Lew YJ, Kim J (2016) Fellow-eye neovascularization in unilateral retinal angiomatous proliferation in a Korean population. Acta Ophthalmol 94:e49\u2013e53","journal-title":"Acta Ophthalmol"},{"key":"5028_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/OPX.0000000000001419","volume":"96","author":"JH Kim","year":"2019","unstructured":"Kim JH, Kim JW, Kim CG, Lee DW (2019) Visual prognosis in the better-seeing eyes of patients with unilateral polypoidal choroidal vasculopathy. Optom Vis Sci 96:686\u2013694","journal-title":"Optom Vis Sci"},{"key":"5028_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/00006982-200509000-00005","volume":"25","author":"NE Gross","year":"2005","unstructured":"Gross NE, Aizman A, Brucker A, Klancnik JM Jr, Yannuzzi LA (2005) Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 25:713\u2013718","journal-title":"Retina"},{"key":"5028_CR22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/IAE.0000000000000488","volume":"35","author":"A Nagiel","year":"2015","unstructured":"Nagiel A, Sarraf D, Sadda SR, Spaide RF, Jung JJ, Bhavsar KV, Ameri H, Querques G, Freund KB (2015) Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography. Retina 35:638\u2013647","journal-title":"Retina"},{"key":"5028_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","volume":"15","author":"RF Spaide","year":"1995","unstructured":"Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA (1995) Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100\u2013110","journal-title":"Retina"},{"key":"5028_CR24","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00417-019-04373-4","volume":"257","author":"JH Kim","year":"2019","unstructured":"Kim JH, Kim JW, Kim CG, Lee DW (2019) Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis. Graefes Arch Clin Exp Ophthalmol 257:1661\u20131669","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5028_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566\u2013583","journal-title":"Am J Ophthalmol"},{"key":"5028_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","volume":"143","author":"R Spaide","year":"2007","unstructured":"Spaide R (2007) Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143:679\u2013680","journal-title":"Am J Ophthalmol"},{"issue":"725\u2013731","key":"5028_CR27","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R (2015) Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol 160(725\u2013731):e721","journal-title":"Am J Ophthalmol"},{"key":"5028_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129361","volume":"10","author":"R Gohil","year":"2015","unstructured":"Gohil R, Crosby-Nwaobi R, Forbes A, Burton B, Hykin P, Sivaprasad S (2015) Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration. PLoS One 10:e0129361","journal-title":"PLoS One"},{"key":"5028_CR29","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ophtha.2015.12.001","volume":"123","author":"S Mueller","year":"2016","unstructured":"Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T (2016) Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment. Ophthalmology 123:876\u2013883","journal-title":"Ophthalmology"},{"key":"5028_CR30","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMp068185","volume":"355","author":"R Steinbrook","year":"2006","unstructured":"Steinbrook R (2006) The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 355:1409\u20131412","journal-title":"N Engl J Med"},{"key":"5028_CR31","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00417-008-0890-8","volume":"246","author":"SY Cohen","year":"2008","unstructured":"Cohen SY, Bremond-Gignac D, Quentel G, Mimoun G, Citterio T, Bisot-Locard S, Beresniak A (2008) Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 246:1527\u20131534","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5028_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaophthalmol.2019.4557","volume":"138","author":"K Mulligan","year":"2019","unstructured":"Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS (2019) Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States. JAMA Ophthalmol 138:40\u201347","journal-title":"JAMA Ophthalmol"},{"key":"5028_CR33","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR (2015) Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122:2514\u20132522","journal-title":"Ophthalmology"},{"key":"5028_CR34","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.ophtha.2013.03.017","volume":"120","author":"MG Maguire","year":"2013","unstructured":"Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF (2013) Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120:2035\u20132041","journal-title":"Ophthalmology"},{"key":"5028_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcjo.2015.11.003","volume":"51","author":"V Chaudhary","year":"2016","unstructured":"Chaudhary V, Gusenbauer K, Mak M, Barbosa J, Mohammad Mohaghegh PS, Popovic M (2016) Waiting room educational media effect on preinjection anxiety for initial intravitreal injections. Can J Ophthalmol 51:71\u201375","journal-title":"Can J Ophthalmol"},{"key":"5028_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5301\/ejo.5001001","volume":"28","author":"S Doguizi","year":"2018","unstructured":"Doguizi S, Sekeroglu MA, Inanc M, Anayol MA, Yilmazbas P (2018) Evaluation of pain during intravitreal aflibercept injections. Eur J Ophthalmol 28:63\u201367","journal-title":"Eur J Ophthalmol"},{"key":"5028_CR37","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41433-018-0126-z","volume":"32","author":"NCI Nguyen","year":"2018","unstructured":"Nguyen NCI, Fabro F, Ambresin A, Ezziat S, Bergin C, Mazzocato C, Mantel I (2018) Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor. Eye (Lond) 32:1544\u20131546","journal-title":"Eye (Lond)"},{"key":"5028_CR38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220\u2013226","journal-title":"Br J Ophthalmol"},{"key":"5028_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/bjophthalmol-2012-302652","volume":"97","author":"T Hikichi","year":"2013","unstructured":"Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Kitamei H, Shioya S (2013) Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. Br J Ophthalmol 97:617\u2013621","journal-title":"Br J Ophthalmol"},{"key":"5028_CR40","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.survophthal.2017.01.008","volume":"62","author":"ASH Tsai","year":"2017","unstructured":"Tsai ASH, Cheung N, Gan ATL, Jaffe GJ, Sivaprasad S, Wong TY, Cheung CMG (2017) Retinal angiomatous proliferation. Surv Ophthalmol 62:462\u2013492","journal-title":"Surv Ophthalmol"},{"key":"5028_CR41","doi-asserted-by":"publisher","first-page":"7589","DOI":"10.1167\/iovs.14-14262","volume":"55","author":"T Hong","year":"2014","unstructured":"Hong T, Mitchell P, Burlutsky G, Samarawickrama C, Wang JJ (2014) Visual impairment and the incidence of falls and fractures among older people: longitudinal findings from the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 55:7589\u20137593","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5028_CR42","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00198-012-2183-7","volume":"24","author":"GC Koh","year":"2013","unstructured":"Koh GC, Tai BC, Ang LW, Heng D, Yuan JM, Koh WP (2013) All-cause and cause-specific mortality after hip fracture among Chinese women and men: the Singapore Chinese Health Study. Osteoporos Int 24:1981\u20131989","journal-title":"Osteoporos Int"},{"key":"5028_CR43","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2009.05.033","volume":"116","author":"H Dadgostar","year":"2009","unstructured":"Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK (2009) Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 116:1740\u20131747","journal-title":"Ophthalmology"},{"key":"5028_CR44","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, Kim K, Sivaprasad S (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623\u20131628","journal-title":"Br J Ophthalmol"},{"key":"5028_CR45","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1097\/IAE.0000000000002239","volume":"39","author":"JH Kim","year":"2019","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW, Kim HS (2019) Long-term visual changes in initially stronger fellow eyes in patients with unilateral type 3 neovascularization. Retina 39:1672\u20131681","journal-title":"Retina"},{"key":"5028_CR46","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1016\/j.ophtha.2016.07.015","volume":"123","author":"M Elshout","year":"2016","unstructured":"Elshout M, van der Reis MI, de Jong-Hesse Y, Webers CA, Schouten JS (2016) Distinguishing between better and worse visual acuity by studying the correlation with quality of life in neovascular age-related macular degeneration. Ophthalmology 123:2408\u20132412","journal-title":"Ophthalmology"},{"key":"5028_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/IAE.0000000000000717","volume":"36","author":"MM Brown","year":"2016","unstructured":"Brown MM, Brown GC, Lieske HB, Tran I, Turpcu A, Colman S (2016) Societal costs associated with neovascular age-related macular degeneration in the United States. Retina 36:285\u2013298","journal-title":"Retina"},{"key":"5028_CR48","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00417-019-04306-1","volume":"257","author":"JH Kim","year":"2019","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2019) Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment. Graefes Arch Clin Exp Ophthalmol 257:1183\u20131189","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5028_CR49","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","volume":"122","author":"Y Kuroda","year":"2015","unstructured":"Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303\u20132310","journal-title":"Ophthalmology"},{"key":"5028_CR50","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjophthalmol-2015-307299","volume":"100","author":"K Hatz","year":"2016","unstructured":"Hatz K, Prunte C (2016) Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 100:1341\u20131345","journal-title":"Br J Ophthalmol"},{"key":"5028_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/08820538.2019.1701045","volume":"35","author":"JH Kim","year":"2020","unstructured":"Kim JH (2020) Results of switching from pro re nata to treat-and-extend regimen in treatment of patients with type 3 neovascularization. Semin Ophthalmol 35:33\u201340","journal-title":"Semin Ophthalmol"},{"key":"5028_CR52","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1167\/iovs.15-18837","volume":"57","author":"J Baek","year":"2016","unstructured":"Baek J, Lee JH, Kim JY, Kim NH, Lee WK (2016) Geographic atrophy and activity of neovascularization in retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 57:1500\u20131505","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5028_CR53","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1097\/IAE.0000000000001104","volume":"36","author":"H Matsumoto","year":"2016","unstructured":"Matsumoto H, Sato T, Morimoto M, Mukai R, Takahashi M, Hiroe T, Ehara K, Takayama M, Mimura K, Kishi S (2016) Treat-and-extend regimen with aflibercept for retinal angiomatous proliferation. Retina 36:2282\u20132289","journal-title":"Retina"},{"key":"5028_CR54","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/IAE.0000000000002582","volume":"40","author":"L Arias","year":"2020","unstructured":"Arias L, Cervera E, Vilimelis JC, Escobar JJ, Escobar AG, Zapata M (2020) Efficacy and safety of a treat-and-extend regimen with aflibercept in treatment-naive patients with type 3 neovascularization: a 52-week, single-arm, multicenter trial. Retina 40:1234\u20131244","journal-title":"Retina"},{"key":"5028_CR55","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR : a randomized controlled trial. Adv Ther 37:1173\u20131187","journal-title":"Adv Ther"},{"key":"5028_CR56","doi-asserted-by":"publisher","first-page":"13264","DOI":"10.1038\/s41598-019-49749-y","volume":"9","author":"SK Baek","year":"2019","unstructured":"Baek SK, Kim JH, Kim JW, Kim CG (2019) Increase in the population of patients with neovascular age-related macular degeneration who underwent long-term active treatment. Sci Rep 9:13264","journal-title":"Sci Rep"},{"key":"5028_CR57","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.survophthal.2019.02.008","volume":"64","author":"J Talks","year":"2019","unstructured":"Talks J, Daien V, Finger RP, Eldem B, Sakamoto T, Cardillo JA, Mitchell P, Wong TY, Korobelnik JF (2019) The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol 64:707\u2013719","journal-title":"Surv Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-05028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-020-05028-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-05028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T04:08:42Z","timestamp":1626235722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-020-05028-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5028"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-05028-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jae Hui Kim: advisory board of Bayer and Novartis. The following authors have no financial disclosure: Ji Hyun Lee, Jong Woo Kim, Chul Gu Kim, Dong Won Lee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board of Kim\u2019s Eye Hospital (Seoul, South Korea). This study was conducted in accordance with the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not obtained in this study. Identifying information about participants was not presented in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Proprietary interest or competing interest"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Meeting presentations"}}]}}